Kyorin Pharma: Commissioned development of GeneSoC®:Agency for Medical Development (AMED)
Kyorin Pharmaceutical: GeneSoC®
Entrusted “Technology development business for advanced medical devices and systems” of the micro-channel type gene quantification device “GeneSoC®”.
Kyorin has recently concluded a contract with the Japan Agency for Medical Research and Development (AMED) for a contract research and development contract for the “Technology Development Business for Advanced Medical Devices and Systems”.
New Coronavirus: Emergency Measures
This project is a project to be implemented by the Cabinet’s decision on the “New Coronavirus Emergency Response Measures (2nd phase)” on March 10.
National Institute of Advanced Industrial Science and Technology: Development
The Japanese government has announced that “GeneSoC®, developed by the National Institute of Advanced Industrial Science and Technology, will be demonstrated in medical institutions and operability confirmed, with the aim of starting use in March.”
About GeneSoC®:
“GeneSoC®” is a micro-channel type thermal developed by AIST.
https://www.kyorin-pharm.co.jp/news/1fac08a608874dca5aea935ffde3ca216759ae0e.pdf
Kyorin to Develop High-Speed PCR System for Coronavirus Detection,
Eyes Launch by March-End
Kyorin Holdings said on March 17 that it will develop a real-time PCR system based on the microfluidic platform,
GeneSoC, for the speedy detection of the novel coronavirus, aiming for its commercial launch by the end of this month.
PHARMA JAPAN